Page last updated: 2024-09-05

zm 241385 and 2-(1-octynyl)adenosine

zm 241385 has been researched along with 2-(1-octynyl)adenosine in 3 studies

Compound Research Comparison

Studies (zm 241385)	Trials (zm 241385)	Recent Studies (post-2010) (zm 241385)	Studies (2-(1-octynyl)adenosine)	Trials (2-(1-octynyl)adenosine)	Recent Studies (post-2010) (2-(1-octynyl)adenosine)
401	3	124	23	0	3

Protein Interaction Comparison

Protein	Taxonomy	zm 241385 (IC50)	2-(1-octynyl)adenosine (IC50)
Adenosine receptor A1	Rattus norvegicus (Norway rat)		2.91

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Donegan, RK; Lieberman, RL	1
Harada, N; Katsuragi, T; Okajima, K	1
Harada, N; Katsuragi, T; Murakami, K; Ohshima, K; Okajima, K; Sato, C; Usune, S	1

Reviews

1 review(s) available for zm 241385 and 2-(1-octynyl)adenosine

Article	Year
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. Journal of medicinal chemistry, 2016, Feb-11, Volume: 59, Issue:3 Topics: Adrenergic Agonists; Adrenergic Antagonists; Adrenergic beta-Antagonists; Animals; Drug Discovery; Glaucoma; Humans; Ligands; Protein Kinase Inhibitors; rho-Associated Kinases; Sympathomimetics	2016

Other Studies

2 other study(ies) available for zm 241385 and 2-(1-octynyl)adenosine

Article	Year
[Adenosine reduces ischemia/reperfusion-induced liver injury by inhibiting leukocyte activation]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1999, Volume: 114 Suppl 1 Topics: Adenosine; Alkynes; Animals; Humans; In Vitro Techniques; Leukocyte Elastase; Liver; Male; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Rats; Rats, Wistar; Receptors, Purinergic P1; Reperfusion Injury; Transaminases; Triazines; Triazoles; Tumor Necrosis Factor-alpha	1999
Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:3 Topics: Adenosine; Alkynes; Animals; Calcium; Cells, Cultured; Chemokine CXCL1; Chemokines, CXC; Chemotactic Factors; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Ischemia; Leukocyte Elastase; Lipopolysaccharides; Liver; Male; Monocytes; Neutrophil Activation; Peroxidase; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Reperfusion Injury; Triazines; Triazoles; Tumor Necrosis Factor-alpha	2000

Article

Year

[Adenosine reduces ischemia/reperfusion-induced liver injury by inhibiting leukocyte activation].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1999, Volume: 114 Suppl 1

Topics: Adenosine; Alkynes; Animals; Humans; In Vitro Techniques; Leukocyte Elastase; Liver; Male; Monocytes; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Rats; Rats, Wistar; Receptors, Purinergic P1; Reperfusion Injury; Transaminases; Triazines; Triazoles; Tumor Necrosis Factor-alpha

1999

Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation.

The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:3

Topics: Adenosine; Alkynes; Animals; Calcium; Cells, Cultured; Chemokine CXCL1; Chemokines, CXC; Chemotactic Factors; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Ischemia; Leukocyte Elastase; Lipopolysaccharides; Liver; Male; Monocytes; Neutrophil Activation; Peroxidase; Phenethylamines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptor, Adenosine A2A; Reperfusion Injury; Triazines; Triazoles; Tumor Necrosis Factor-alpha

2000